Compare DexCom, Inc. (DXCM) vs Newegg Commerce Inc (NEGG) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

NEGG trades at $13.53, down 3.91% today, with a bearish technical signal from moving averages. The company reported Q1 2026 EPS of $0.37, beating expectations, but faces profitability challenges with a net margin of 0.39%. Recent initiatives include AI shopping features and the FantasTech sale. Cash flow from operations remains negative at -$26.97M for 2025, though net cash flow improved to $8.91M.

Outlook: NEGG shows modest revenue stability but weak profitability and negative operating cash flow pose risks. The single analyst rating is Buy, yet technical indicators suggest caution. Investment appeal hinges on margin improvement and sustainable cash generation amid competitive e-commerce pressures.